Cargando…
Immunotherapy with NK cells: recent developments in gene modification open up new avenues
Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual kill...
Autores principales: | Reindl, Lisa Marie, Albinger, Nawid, Bexte, Tobias, Müller, Stephan, Hartmann, Jessica, Ullrich, Evelyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781759/ https://www.ncbi.nlm.nih.gov/pubmed/33457093 http://dx.doi.org/10.1080/2162402X.2020.1777651 |
Ejemplares similares
-
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
por: Wendel, Philipp, et al.
Publicado: (2021) -
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021) -
P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.
por: Albinger, Nawid, et al.
Publicado: (2023) -
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
por: Bexte, Tobias, et al.
Publicado: (2022) -
Unleashing the power of NK cells in anticancer immunotherapy
por: Vogler, Meike, et al.
Publicado: (2021)